ATE208400T1 - Pro-medikamente für cck-antagonisten - Google Patents
Pro-medikamente für cck-antagonistenInfo
- Publication number
- ATE208400T1 ATE208400T1 AT91918120T AT91918120T ATE208400T1 AT E208400 T1 ATE208400 T1 AT E208400T1 AT 91918120 T AT91918120 T AT 91918120T AT 91918120 T AT91918120 T AT 91918120T AT E208400 T1 ATE208400 T1 AT E208400T1
- Authority
- AT
- Austria
- Prior art keywords
- pro
- agents
- useful
- drugs
- treatment
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940002612 prodrug Drugs 0.000 abstract 4
- 239000000651 prodrug Substances 0.000 abstract 4
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 1
- 102100021022 Gastrin Human genes 0.000 abstract 1
- 108010052343 Gastrins Proteins 0.000 abstract 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010033664 Panic attack Diseases 0.000 abstract 1
- IMMPMHKLUUZKAZ-WMZOPIPTSA-N Trp-Phe Chemical class C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)N)C(O)=O)C1=CC=CC=C1 IMMPMHKLUUZKAZ-WMZOPIPTSA-N 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 229940005529 antipsychotics Drugs 0.000 abstract 1
- 239000003699 antiulcer agent Substances 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 229960001948 caffeine Drugs 0.000 abstract 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 abstract 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229960003920 cocaine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 abstract 1
- 229960003529 diazepam Drugs 0.000 abstract 1
- 210000004211 gastric acid Anatomy 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960002715 nicotine Drugs 0.000 abstract 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 229940005483 opioid analgesics Drugs 0.000 abstract 1
- 208000019906 panic disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0205—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)3-C(=0)-, e.g. statine or derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/021—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)n-C(=0)-, n being 5 or 6; for n > 6, classification in C07K5/06 - C07K5/10, according to the moiety having normal peptide bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57631590A | 1990-08-31 | 1990-08-31 | |
| US07/726,653 US5340825A (en) | 1990-08-31 | 1991-07-12 | Pro drugs for CCK antagonists |
| PCT/US1991/006178 WO1992004038A1 (en) | 1990-08-31 | 1991-08-29 | Pro-drugs for cck antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE208400T1 true ATE208400T1 (de) | 2001-11-15 |
Family
ID=27076930
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT91918120T ATE208400T1 (de) | 1990-08-31 | 1991-08-29 | Pro-medikamente für cck-antagonisten |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US5554643A (de) |
| EP (1) | EP0546108B1 (de) |
| JP (1) | JP3356431B2 (de) |
| AT (1) | ATE208400T1 (de) |
| AU (1) | AU649077B2 (de) |
| CA (1) | CA2088980C (de) |
| DE (1) | DE69132805T2 (de) |
| DK (1) | DK0546108T3 (de) |
| ES (1) | ES2167312T3 (de) |
| IE (1) | IE913079A1 (de) |
| NO (1) | NO300324B1 (de) |
| NZ (1) | NZ239591A (de) |
| PT (1) | PT98831B (de) |
| WO (1) | WO1992004038A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992004038A1 (en) * | 1990-08-31 | 1992-03-19 | Warner-Lambert Company | Pro-drugs for cck antagonists |
| WO1993000897A1 (en) * | 1991-07-12 | 1993-01-21 | Warner-Lambert Company | Cholecystokinin antagonists useful in the treatment of panic attacks |
| US5217957A (en) * | 1991-08-20 | 1993-06-08 | Warner-Lambert Company | Cholecystokinin antagonists useful for treating depression |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| EP0655055B1 (de) * | 1992-08-13 | 2000-11-29 | Warner-Lambert Company | Tachykinin antagonistes |
| TW281669B (de) * | 1993-02-17 | 1996-07-21 | Chugai Pharmaceutical Co Ltd | |
| US6869957B1 (en) | 1993-11-17 | 2005-03-22 | Eli Lilly And Company | Non-peptide tachykinin receptor antagonists |
| US6403577B1 (en) | 1993-11-17 | 2002-06-11 | Eli Lilly And Company | Hexamethyleneiminyl tachykinin receptor antagonists |
| US6129685A (en) * | 1994-02-09 | 2000-10-10 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
| US7077822B1 (en) | 1994-02-09 | 2006-07-18 | The University Of Iowa Research Foundation | Stereotactic hypothalamic obesity probe |
| CA2152765A1 (en) | 1994-06-30 | 1995-12-31 | Jeroen Elisabeth-Joseph Knops | Methods for treating a physiological disorder associated with beta amyloid peptide |
| US7109326B2 (en) * | 1997-04-15 | 2006-09-19 | Genentech, Inc. | Halo-alkoxycarbonyl prodrugs |
| WO2008031221A1 (en) | 2006-09-12 | 2008-03-20 | Cephalin Pharmaceuticals Inc. | Isovaline for treatment of pain |
| JP7509340B2 (ja) * | 2016-03-14 | 2024-07-02 | ピボット ホールディングス エルエルシー | トリゴネリンベースの化合物 |
| WO2020070557A1 (en) * | 2018-10-02 | 2020-04-09 | Q Biomed Inc. | Modified therapeutic agent analogs of mefenamic acid |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2364659A1 (fr) * | 1976-09-21 | 1978-04-14 | Commissariat Energie Atomique | Medicament antagoniste de l'action de la gastrine et des polypeptides apparentes |
| US4757151A (en) * | 1985-11-14 | 1988-07-12 | Warner-Lambert Company | 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl] |
| EP0336356A3 (de) * | 1988-04-05 | 1991-09-25 | Abbott Laboratories | Tryptophan-Derivate, verwendbar als CCK-Gegner |
| US4997950A (en) * | 1989-04-20 | 1991-03-05 | Richard Finbar Murphy | Novel C-terminal gastrin antagonists |
| NZ234264A (en) * | 1989-06-29 | 1993-05-26 | Warner Lambert Co | N-substituted cycloalkyl and polycycloalkyl alpha-substituted trp-phe- and phenethylamine derivatives, and pharmaceutical compositions |
| US5278316A (en) * | 1989-06-29 | 1994-01-11 | Warner-Lambert Company | N-substituted cycloalkyl and polycycloalkyl alpha-substituted Trp-Phe- and phenethylamine derivatives |
| WO1992004038A1 (en) * | 1990-08-31 | 1992-03-19 | Warner-Lambert Company | Pro-drugs for cck antagonists |
-
1991
- 1991-08-29 WO PCT/US1991/006178 patent/WO1992004038A1/en active IP Right Grant
- 1991-08-29 AU AU87250/91A patent/AU649077B2/en not_active Ceased
- 1991-08-29 AT AT91918120T patent/ATE208400T1/de not_active IP Right Cessation
- 1991-08-29 ES ES91918120T patent/ES2167312T3/es not_active Expired - Lifetime
- 1991-08-29 DE DE69132805T patent/DE69132805T2/de not_active Expired - Fee Related
- 1991-08-29 NZ NZ23959191A patent/NZ239591A/en unknown
- 1991-08-29 EP EP91918120A patent/EP0546108B1/de not_active Expired - Lifetime
- 1991-08-29 DK DK91918120T patent/DK0546108T3/da active
- 1991-08-29 JP JP51666591A patent/JP3356431B2/ja not_active Expired - Fee Related
- 1991-08-29 CA CA002088980A patent/CA2088980C/en not_active Expired - Fee Related
- 1991-08-30 PT PT98831A patent/PT98831B/pt not_active IP Right Cessation
- 1991-08-30 IE IE307991A patent/IE913079A1/en not_active Application Discontinuation
-
1993
- 1993-02-26 NO NO930710A patent/NO300324B1/no not_active IP Right Cessation
-
1994
- 1994-04-13 US US08/227,211 patent/US5554643A/en not_active Expired - Fee Related
-
1996
- 1996-06-10 US US08/661,254 patent/US5726200A/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JPH06501007A (ja) | 1994-01-27 |
| JP3356431B2 (ja) | 2002-12-16 |
| NO930710D0 (no) | 1993-02-26 |
| CA2088980A1 (en) | 1992-03-01 |
| AU649077B2 (en) | 1994-05-12 |
| US5554643A (en) | 1996-09-10 |
| EP0546108A1 (de) | 1993-06-16 |
| PT98831B (pt) | 1999-02-26 |
| NZ239591A (en) | 1994-07-26 |
| EP0546108B1 (de) | 2001-11-07 |
| CA2088980C (en) | 2002-04-16 |
| AU8725091A (en) | 1992-03-30 |
| DE69132805D1 (de) | 2001-12-13 |
| DK0546108T3 (da) | 2002-02-18 |
| NO930710L (no) | 1993-04-21 |
| EP0546108A4 (en) | 1993-09-22 |
| US5726200A (en) | 1998-03-10 |
| DE69132805T2 (de) | 2002-10-24 |
| IE913079A1 (en) | 1992-03-11 |
| PT98831A (pt) | 1992-08-31 |
| NO300324B1 (no) | 1997-05-12 |
| WO1992004038A1 (en) | 1992-03-19 |
| ES2167312T3 (es) | 2002-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI916060A0 (fi) | Foerfarande foer framstaellning av n-substituerade cykloalkyl- och polycykloalkyl-a-substituerade trp-phe- och fenetylaminderivat. | |
| ATE208400T1 (de) | Pro-medikamente für cck-antagonisten | |
| DK0975595T3 (da) | Kokainanaloger | |
| MY123642A (en) | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them. | |
| KR20030022371A (ko) | 벤질리덴아미노구아니딘 및 히드록시구아니딘의멜라노코르틴 수용체 리간드로서의 용도 | |
| SI21923B (sl) | Paroksetin hidroklorid anhidrat brez vezanega organskega topila | |
| RU2005134230A (ru) | Ацилированные производные спиропиперидина как агонисты рецептора меланокортина-4 | |
| GB9202791D0 (en) | Compounds | |
| EP0303465A3 (de) | Phenethanolamin-Derivate | |
| WO2000055162A3 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| DE2808111A1 (de) | Neue dipeptidderivate und deren verwendung zur messung der enzymatischen aktivitaet | |
| CN110272425A (zh) | 吡啶酰基八氢吡咯并[3,4-c]吡咯衍生物及其用途 | |
| DE69810629T2 (de) | Beta-alkoxyacrylate gegen malaria | |
| EP0531228B1 (de) | Thioharnstoffderivate und sie enthaltendes, antimikrobielles und antiulcerogenes Mittel | |
| JP2000256326A (ja) | アルカロイド系化合物を含んでなるσレセプター作用薬 | |
| RU2678969C1 (ru) | Антиаритмическое средство на основе гибридной молекулы амлодипина с (7-метоксикумарин-4-ил)уксусной кислотой | |
| ES2126577T3 (es) | Analogos alquilidenicos de 1'-aminoespiro(isoquinolino-4(1h),3'-pirrolidino)-1,2',3,5'(2h)-tetronas utiles como inhibidores de la aldosa reductasa in vivo. | |
| FR2647785B1 (fr) | Nouveaux derives de la pyrrolidone, leur procede de preparation et les compositions pharmaceutiques les renfermant | |
| ES531447A0 (es) | Procedimiento de preparar derivados de n-cicloalcoilmetil-2 oxo-3 diaril 5-6 as triacina | |
| RU93005013A (ru) | 1-аминоспиро[изохинолин-4(1н)3-пирролидин-1,2,3,5'(2н)-тетроны] и их аналоги, способ их получения и фармацевтическая композиция | |
| EP0308159A3 (de) | Substituierte Pyridine als Dopamin-beta-hydroxylase-Inhibitoren | |
| CN117440811A (zh) | 用于治疗与核糖体障碍相关的贫血的组合物和方法 | |
| EP0643579A1 (de) | Triazol substituierte quinolin-derivate | |
| JP2001527076A (ja) | 海綿動物から単離されるアスマリンａ及びｂを含む細胞毒性アルカロイド誘導体 | |
| NO930711L (no) | Aminosyrederivater ringsluttet i den c-terminale ende |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |